Evidence map›Paper›PMID 41094190›Full record

ArticleBone marrow transplantation2026

Transplant conditioning intensity (TCI) score predicts allo-HCT outcomes in patients with myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT.

Patryk Sobieralski, Tomasz Czerw, Luuk Gras, Linda Koster, Nicolaus Kröger, Thomas Schroeder, Lone Friis, Elisabetta Metafuni, Jakob Passweg, Marie Robin and 15 more

Abstract read
In one paragraph

Article in Bone marrow transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Patryk SobieralskiMedical University of Gdańsk, Gdańsk, Poland. patryk.sobieralski@gumed.edu.pl.ORCID 0000-0001-9112-5017
Tomasz CzerwMaria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, Poland.ORCID 0000-0003-3108-4035
Luuk GrasEBMT Leiden Study Unit, Leiden, the Netherlands.
Linda KosterEBMT Leiden Study Unit, Leiden, the Netherlands.
Nicolaus KrögerUniversity Hospital Eppendorf, Hamburg, Germany.
Thomas SchroederUniversity Hospital Essen, Duesseldorf, Germany.
Lone FriisRigshospitalet, Copenhagen, Denmark.
Elisabetta MetafuniFondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.ORCID 0000-0002-4780-1273
Jakob PasswegUniversity Hospital Basel, Basel, Switzerland.ORCID 0000-0001-7092-3351
Marie RobinHospital Saint-Louis, Service d'hématologie-greffe, Université de Paris Cité, Paris, France.ORCID 0000-0003-1388-9876
Matthias StelljesUniversity of Muenster, Muenster, Germany.ORCID 0000-0002-9331-5145
Annoek E C BroersErasmus MC Cancer Institute, Rotterdam, the Netherlands.
Patrice ChevallierCHU Nantes, Nantes, France.ORCID 0000-0003-3142-5581
Robert ZeiserUniversity of Freiburg, Freiburg, Germany.ORCID 0000-0001-6565-3393
Marie Therese RubioCHRU NANCY, Nancy, France.ORCID 0000-0003-3732-5442
Mareike VerbeekTUM University Hospital Munich, School of Medicine, Department of Hematology and Oncology, Munich, Germany.
Ipek Yonal-HindilerdenIstanbul University Faculty of Medicine, Department of Adult Hematopoietic Stem Cell Transplantation Unit, Istanbul, Turkey.ORCID 0000-0003-1353-2367
Domenico PastorePerrino Hospital, Brindisi, Italy.
Jan ZauchaMedical University of Gdańsk, Gdańsk, Poland.
Kavita RajUniversity College London Hospitals NHS Trust, London, UK.ORCID 0000-0002-8258-354X
Joanna Drozd-SokołowskaUniversity Clinical Centre, Medical University of Warsaw, Warsaw, Poland.ORCID 0000-0002-4562-6264
Giorgia BattipagliaHematology Department, Federico II University of Naples, Naples, Italy.ORCID 0000-0002-0695-3879
Nicola PolverelliUnit of Bone Marrow Transplantation and Cellular Therapies-Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.ORCID 0000-0001-6297-9697
Juan Carlos Hernández-BoludaDepartment of Hematology, Hospital Clínico Universitario, Valencia, Spain. hernandez_jca@gva.es.ORCID 0000-0002-4289-3113
Donal P McLornanUniversity College London Hospitals NHS Trust, London, UK.ORCID 0000-0003-1224-091X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Outcomes in myelofibrosis (MF) patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) appear unaffected by the intensity of the preparative regimen, defined traditionally as myeloablative (MAC) or reduced intensity conditioning (RIC). The Transplant Conditioning Intensity (TCI) index is an objective tool offering a precise measure of conditioning intensity. We explored the potential association between TCI score and overall survival (OS), progression-free survival (PFS), cumulative incidence of relapse (CIR) and non-relapse mortality (NRM) in 2454 MF patients undergoing allo-HCT between 2012 and 2021, selected from the EBMT registry. Patients receiving TCI-intermediate/high regimens had similar OS (HR 1.12, 95% CI 0.97-1.30) and PFS (HR 1.00, 95% CI 0.88-1.14) compared to TCI-low regimens. However, TCI-intermediate/high regimens were associated with lower risk of relapse (HR 0.74, 95% CI 0.61-0.91, p = 0.008) and higher risk of NRM (HR 1.24, 95% CI 1.04-1.48, p = 0.02). Our findings suggest that the TCI score provides a more clinically relevant stratification of conditioning intensity than the conventional MAC/RIC classification. While higher intensity TCI regimens are associated with lower RI, this benefit is offset by increased NRM, resulting in no survival advantage. However, the TCI index may enable a more personalized approach to conditioning regimen selection by balancing relapse risk with patient frailty.

Indexed as

Hematopoietic Stem Cell TransplantationPrimary MyelofibrosisTransplantation ConditioningAdultAgedFemaleHumansMaleMiddle AgedRegistriesTransplantation, HomologousTreatment Outcome

Identifiers

PMID41094190
PMCPMC12819149

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.